ClinicalTrials.gg
CompletedNCT00015171Updated Jan 16, 2017

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

A Phase 3 interventional study of Buprenorphine/naloxone in Heroin Dependence and Substance-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2017-01-16.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
0
Ages
18 Years to 59 Years
Sex
All
01

Study summary

The purpose of this study is the use of buprenorphine/naloxone in treatment of opioid dependence.

Read the detailed description

The objective of this study is to determine the safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment.

02

Conditions studied

  • Heroin Dependence
  • Substance-Related Disorders

Keywords

  • opioid dependence
03

In context

Heroin Dependence

90 studies on the registry are indexed under Heroin Dependence; 1 is open to participants now.

Browse Heroin Dependence studies →

Lead sponsor

National Institute on Drug Abuse (NIDA) is the lead sponsor of 393 studies on the registry; 19 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

diagnosis of current opiate dependence males and non-pregnant, non-nursing female 18-59 yrs of age

Exclusion criteria

Exclusion Criteria:

Any significant medical condition or ALT levels greater than 3x's the level Current Axis I diagnosis other than opiate, caffeine or nicotine dependence

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
Double
Enrollment
0 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Craving

  2. Drug use

  3. Retention

  4. Opioid withdrawal

  5. Subjective rating

07

Study locations

1 site
  • New York MDRU
    New York, New York 10010, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00015171
Collaborators
New York MDRU
First posted
Apr 18, 2001
Start date
Apr 1996
Primary completion
May 1997
Completion
Jun 1997
Last update
Jan 16, 2017

Study contacts

John Rotrosen, M.D.
principal investigator · New York MDRU
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Buprenorphine · Naloxone

Start the discussion